short term prednisolon in itp

Comparison of the Efficiency of Short-Term and Two-Week Oral Prednisolone Use to Manage Newly Diagnosed Immune Thrombocytopenia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230718058831N1

Enrollment

Registered

2023-10-28

Start date

2022-09-23

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment Patients with acute immune thrombocytopenia. Immune thrombocytopenic purpura

Interventions

Intervention 1: Intervention group:The study is designed in the form of a coincidental and open label. All patients with a newly diagnosed immune thrombocytopenic condition were aged 1 month to 15 yea

Eligibility

Sex/Gender

All

Age

1 Months to 14 Years

Inclusion criteria

Inclusion criteria: childeren with acuteImmune Thrombocytopenia

Exclusion criteria

Exclusion criteria: Patients with active infections and septicemia patients with positive antinuclear antibody patients with Evans syndrome Patients with chronic immune thrombocytopenia Patients with positive glue culture

Design outcomes

Primary

Measure	Time frame
Platelet count of patients after a short course of prednisolone. Timepoint: Comment on the number of blood platelets at different time points before the start and days 2, 7, 30 and 60 after the start of the treatment period. Method of measurement: Compelete blood count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhatere Tavajohi

Shahid Beheshti University of Medical Sciences

khtavajohi@gmail.com+98 912 050 4872

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026